ARCHIVES

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

CHOP Gets Concept Approval; DCT Release RFAs for Lung, Colon Drug Discovery Groups

October 24, 1986

Barakat Named Deputy Physician-in-Chief Of Memorial Sloan-Kettering’s Regional Care Network

October 18, 2013

NCI Breast Cancer Overview Report Competed

August 5, 1988

Healy’s “Save Bob” Campaign

January 6, 1995

In the Cancer Centers: Rosen Moves To City Of Hope

November 1, 2013

Trials Approved by NCI CTEP For the Month of December

December 30, 2011